Metformin and Cancer: Mounting Evidence Against an Association
2014; American Diabetes Association; Volume: 37; Issue: 7 Linguagem: Inglês
10.2337/dc14-0500
ISSN1935-5548
Autores Tópico(s)PI3K/AKT/mTOR signaling in cancer
ResumoMetformin, a biguanide derived from the French lilac, has become the preferred first-line therapy for the treatment of type 2 diabetes (1). This drug is inexpensive, has an excellent safety profile, and can be safely combined with other antidiabetes agents (2). As a result, it has become the most widely prescribed antidiabetes drug worldwide. In addition to metformin’s well-established antidiabetes effects, there has been considerable interest in its antitumor properties. Such interest started from a short report of an observational study published in 2005 that suggested that the use of metformin was associated with a 23% decreased risk of any cancer (3). Since then, a large number of observational studies have been published with several “corroborating” a possible decreased incidence of cancer with this drug (4). In parallel, several laboratory studies have also suggested that metformin has antineoplastic activity, although doses used in such experiments were typically higher than the conventional doses used in the treatment of type 2 diabetes (5). Nonetheless, this apparent convergence of evidence from both observational and laboratory studies has led some to call for large randomized clinical trials (RCTs) of metformin in cancer prevention and treatment (6–9). However, a careful assessment of the observational studies conducted to date point to some important time-related biases that systematically exaggerated the reported antitumor effects of metformin (10). Time-related biases, such as immortal time bias, time window bias, and time lag bias, have been previously described in studies of diabetes treatment (10) and in other therapeutic areas (11–14). These biases result from not properly classifying exposure during the follow-up of a cohort study or from …
Referência(s)